Developing immunologically inert adeno-associated virus (AAV) vectors for gene therapy: Possibilities and limitations

Current Pharmaceutical Biotechnology

Volumn 14, Issue 12, 2014, Pages 1072-1082

  Selot, Ruchita S ^a   Hareendran, Sangeetha ^a   Jayandharan, Giridhara R ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Adeno associated virus; B cell response; Gene therapy; Immune evasion; Immune response; Stealth vector; T cell response

Indexed keywords

BORTEZOMIB; CD4 ANTIGEN; CD40 ANTIGEN; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEOXYRIBONUCLEASE I; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; METFORMIN; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; VERY LATE ACTIVATION ANTIGEN 5;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL METABOLISM; CELLULAR IMMUNITY; CHEMICAL MODIFICATION; CRYOELECTRON MICROSCOPY; CYTOTOXICITY; DNA SHUFFLING; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; NONHUMAN; OVERLAPPING GENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RECEPTOR BINDING; REGULATORY T LYMPHOCYTE; REVIEW; SEROTYPE; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE ACTIVATION; TRANSGENE; VIRUS CAPSID; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; CHEMISTRY; DEPENDOPARVOVIRUS; DIRECTED MOLECULAR EVOLUTION; GENE VECTOR; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MOLECULAR GENETICS; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CAPSID; DEPENDOVIRUS; DIRECTED MOLECULAR EVOLUTION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC MEMORY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; T-LYMPHOCYTES;

EID: 84903710267     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140327141710     Document Type: Review

References (114)

1. Biasco, L.; Baricordi, C.; Aiuti, A. Retroviral integrations in gene therapy trials. Mol. Ther., 2012, 20(4), 709-716.
2. Suzuki, M.; Rooney, C.M. Adenovirus immunity: X marks the spot. Mol. Ther., 2012, 20(12), 2197-2198.
3. Snyder, R.O.; Audit, M.; Francis, J.D. RAAV Vector product characterization and stability studies #. In T Adeno-Associated Virus, 2011, 807, 405-428.
4. Xie, Q.; Bu, W.; Bhatia, S.; Hare, J.; Somasundaram, T.; Azzi, A.; Chapman, M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A, 2002, 99(16), 10405-10410.
5. O'Donnell, J.; Taylor, K.A.; Chapman, M.S. Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology, 2009, 385(2), 434-43.
6. Calcedo, R.; Wilson, J.M. Humoral immune response to AAV. Front. Immunol., 2013, 4, 341.
7. Zhong, L.; Jayandharan, G.R.; Aslanidi, G.V.; Zolotukhin, S.; Herzog, R.W.; Srivastava, A. Development of novel recombinant AAV vectors and strategies for the potential gene therapy of hemophilia. J. Genet. Syndr. Gene. Ther., 2012, S1.
8. Johnson, J. S.; Gentzsch, M.; Zhang, L.; Ribeiro, C. M.; Kantor, B.; Kafri, T.; Pickles, R.J.; Samulski, R.J. AAV exploits subcellular stress associated with inflammation, endoplasmic reticulum expansion, and misfolded proteins in models of cystic fibrosis. PLoS Pathog., 2011, 7(5), e1002053.
9. Mueller, C.; Flotte, T. R. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD, 2013, 10 (Suppl 1), 44-49.
10. Coune, P.G.; Schneider, B.L.; Aebischer, P. Parkinson's disease: Gene therapies. Cold Spring Harb. Perspect. Med., 2012, 2(4).
11. Mendell, J.R.; Campbell, K.; Rodino-Klapac, L.; Sahenk, Z.; Shilling, C.; Lewis, S.; Bowles, D.; Gray, S.; Li, C.; Galloway, G.; Malik, V.; Coley, B.; Clark, K.R.; Li, J.; Xiao, X.; Samulski, J.; McPhee, S.W.; Samulski, R.J.; Walker, C.M. Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med., 2010, 363(15), 1429-37.
12. Chung, D.C.; Lee, V.; Maguire, A.M. Recent advances in ocular gene therapy. Curr. Opin. Ophthalmol., 2009, 20(5), 377-381.
13. Jacobson, S.G.; Boye, S.L.; Aleman, T.S.; Conlon, T.J.; Zeiss, C.J.; Roman, A.J.; Cideciyan, A.V.; Schwartz, S.B.; Komaromy, A.M.; Doobrajh, M.; Cheung, A.Y.; Sumaroka, A.; Pearce-Kelling, S.E.; Aguirre, G.D.; Kaushal, S.; Maguire, A.M.; Flotte, T.R.; Hauswirth, W.W. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum. Gene. Ther., 2006, 17(8), 845-858.
14. Maguire, A.M.; Simonelli, F.; Pierce, E.A.; Pugh, E.N., Jr.; Mingozzi, F.; Bennicelli, J.; Banfi, S.; Marshall, K.A.; Testa, F.; Surace, E.M.; Rossi, S.; Lyubarsky, A.; Arruda, V.R.; Konkle, B.; Stone, E.; Sun, J.; Jacobs, J.; Dell'Osso, L.; Hertle, R.; Ma, J.X.; Redmond, T.M.; Zhu, X.; Hauck, B.; Zelenaia, O.; Shindler, K.S.; Maguire, M.G.; Wright, J.F.; Volpe, N.J.; McDonnell, J.W.; Auricchio, A.; High, K.A.; Bennett, J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 2008, 358(21), 2240-2248.
15. Bennett, J.; Ashtari, M.; Wellman, J.; Marshall, K.A.; Cyckowski, L.L.; Chung, D.C.; McCague, S.; Pierce, E.A.; Chen, Y.; Bennicelli, J.L.; Zhu, X.; Ying, G.S.; Sun, J.; Wright, J.F.; Auricchio, A.; Simonelli, F.; Shindler, K.S.; Mingozzi, F.; High, K.A.; Maguire, A.M. AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 2012, 4(120), 120ra15.
16. Manno, C.S.; Pierce, G.F.; Arruda, V.R.; Glader, B.; Ragni, M.; Rasko, J.J.; Ozelo, M.C.; Hoots, K.; Blatt, P.; Konkle, B.; Dake, M.; Kaye, R.; Razavi, M.; Zajko, A.; Zehnder, J.; Rustagi, P.K.; Nakai, H.; Chew, A.; Leonard, D.; Wright, J.F.; Lessard, R.R.; Sommer, J.M.; Tigges, M.; Sabatino, D.; Luk, A.; Jiang, H.; Mingozzi, F.; Couto, L.; Ertl, H.C.; High, K.A.; Kay, M.A. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 2006, 12(3), 342-347.
17. Gao, G.; Alvira, M.R.; Somanathan, S.; Lu, Y.; Vandenberghe, L. H.; Rux, J.J.; Calcedo, R.; Sanmiguel, J.; Abbas, Z.; Wilson, J.M. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A, 2003, 100(10), 6081-6086.
18. Zincarelli, C.; Soltys, S.; Rengo, G.; Rabinowitz, J. E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther., 2008, 16(6), 1073-1080.
19. Mitchell, A.M.; Nicolson, S.C.; Warischalk, J.K.; Samulski, R.J. AAV's anatomy: Roadmap for optimizing vectors for translational success. Curr. Gene Ther., 2010, 10(5), 319-340.
20. Maman, Y.; Blancher, A.; Benichou, J.; Yablonka, A.; Efroni, S.; Louzoun, Y. Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins. J. Virol., 2011, 85(9), 4558-4566.
21. Vider-Shalit, T.; Almani, M.; Sarid, R.; Louzoun, Y. The HIV hide and seek game: An immunogenomic analysis of the HIV epitope repertoire. AIDS, 2009, 23(11), 1311-1318.
22. Elemans, M.; Seich Al Basatena, N. K.; Asquith, B. The efficiency of the human CD8+ T cell response: How should we quantify it, what determines it, and does it matter? PLoS Comput. Biol., 2012, 8(2), e1002381.
23. Cardinaud, S.; Consiglieri, G.; Bouziat, R.; Urrutia, A.; Graff-Dubois, S.; Fourati, S.; Malet, I.; Guergnon, J.; Guihot, A.; Katlama, C.; Autran, B.; van Endert, P.; Lemonnier, F.A.; Appay, V.; Schwartz, O.; Kloetzel, P.M.; Moris, A. CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. PLoS Pathog., 2011, 7(5).
24. Wang, J.P.; Bowen, G.N.; Zhou, S.; Cerny, A.; Zacharia, A.; Knipe, D.M.; Finberg, R.W.; Kurt-Jones, E.A. Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J. Virol., 2012, 86(4), 2273-2281.
25. Bigley, N.J. Complexity of Interferon-gamma Interactions with HSV-1. Front Immunol., 2014, 5, 15.
26. Jayandharan, G.R.; Aslanidi, G.; Martino, A.T.; Jahn, S.C.; Perrin, G.Q.; Herzog, R.W.; Srivastava, A. Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc. Natl. Acad. Sci. U.S.A, 2011, 108(9), 3743-3748.
27. Gao, G. P.; Alvira, M. R.; Wang, L.; Calcedo, R.; Johnston, J.; Wilson, J. M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U S A, 2002, 99(18), 11854-9.
28. Goncalves, M. A., Adeno-associated virus: From defective virus to effective vector. Virol. J., 2005, 2, 43.
29. Choi, V.W.; McCarty, D.M.; Samulski, R.J. AAV hybrid serotypes: Improved vectors for gene delivery. Curr. Gene. Ther., 2005, 5(3), 299-310.
30. Lochrie, M.A.; Tatsuno, G.P.; Arbetman, A.E.; Jones, K.; Pater, C.; Smith, P.H.; McDonnell, J.W.; Zhou, S.Z.; Kachi, S.; Kachi, M.; Campochiaro, P.A.; Pierce, G.F.; Colosi, P. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5. Virology, 2006, 353(1), 68-82.
31. Kern, A.; Schmidt, K.; Leder, C.; Muller, O.J.; Wobus, C.E.; Bettinger, K.; Von der Lieth, C.W.; King, J.A.; Kleinschmidt, J.A. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol., 2003, 77(20), 11072-11081.
32. Opie, S.R.; Warrington, K.H., Jr.; Agbandje-McKenna, M.; Zolotukhin, S.; Muzyczka, N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol., 2003, 77(12), 6995-7006.
33. Van Vliet, K.; Blouin, V.; Agbandje-McKenna, M.; Snyder, R.O. Proteolytic mapping of the adeno-associated virus capsid. Mol. Ther., 2006, 14(6), 809-821.
34. Summerford, C.; Samulski, R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol., 1998, 72(2), 1438-1445.
35. Asokan, A.; Schaffer, D.V.; Samulski, R.J. The AAV vector toolkit: Poised at the clinical crossroads. Mol. Ther., 2012, 20(4), 699-708.
36. Moskalenko, M.; Chen, L.; van Roey, M.; Donahue, B.A.; Snyder, R.O.; McArthur, J.G.; Patel, S.D. Epitope mapping of human antiadeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J. Virol., 2000, 74(4), 1761-6.
37. Li, C.; Diprimio, N.; Bowles, D.E.; Hirsch, M.L.; Monahan, P.E.; Asokan, A.; Rabinowitz, J.; Agbandje-McKenna, M.; Samulski, R. J. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. J. Virol., 2012, 86(15), 7752-7759.
38. Aslanidi, G.V.; Rivers, A.E.; Ortiz, L.; Song, L.; Ling, C.; Govindasamy, L.; Van Vliet, K.; Tan, M.; Agbandje-McKenna, M.; Srivastava, A. Optimization of the capsid of recombinant adenoassociated virus 2 (AAV2) vectors: The final threshold? PLoS One, 2013, 8(3), e59142.
39. Gabriel, N.; Hareendran, S.; Sen, D.; Gadkari, R.A.; Sudha, G.; Selot, R.; Hussain, M.; Dhaksnamoorthy, R.; Samuel, R.; Srinivasan, N.; Srivastava, A.; Jayandharan, G.R. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Hum. Gene Ther. Methods, 2013, 24(2), 80-93.
40. Sen, D.; Gadkari, R.A.; Sudha, G.; Gabriel, N.; Kumar, Y.S.; Selot, R.; Samuel, R.; Rajalingam, S.; Ramya, V.; Nair, S.C.; Srinivasan, N.; Srivastava, A.; Jayandharan, G.R. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo. Hum. Gene Ther. Methods, 2013, 24(2), 104-116.
41. Martino, A.T.; Basner-Tschakarjan, E.; Markusic, D.M.; Finn, J.D.; Hinderer, C.; Zhou, S.; Ostrov, D.A.; Srivastava, A.; Ertl, H.C.; Terhorst, C.; High, K.A.; Mingozzi, F.; Herzog, R.W. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood, 2013, 121(12), 2224-2233.
42. Zhong, L.; Li, B.; Mah, C.S.; Govindasamy, L.; Agbandje-McKenna, M.; Cooper, M.; Herzog, R.W.; Zolotukhin, I.; Warrington, K.H., Jr.; Weigel-Van Aken, K.; Hobbs, J.A.; Zolotukhin, S.; Muzyczka, N.; Srivastava, A. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A, 2008, 105(22), 7827-7832.
43. Markusic, D.M.; Herzog, R.W.; Aslanidi, G.V.; Hoffman, B.E.; Li, B.; Li, M.; Jayandharan, G.R.; Ling, C.; Zolotukhin, I.; Ma, W.; Zolotukhin, S.; Srivastava, A.; Zhong, L. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther., 2010, 18(12), 2048-2056.
44. Thiery, V.D.F.M.; Nisha, N.; Jessica, W.; Haneke, E.; Omid, G.; Kathy, H.; Marinee, K. C. Soving the T cell problem: Generation of immune stealth AAV. ASGCT Abstracts, 2012, 21, (Suppl. 1), S3.
45. Huttner, N. A.; Girod, A.; Perabo, L.; Edbauer, D.; Kleinschmidt, J. A.; Buning, H.; Hallek, M. Genetic modifications of the adenoassociated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther., 2003, 10(26), 2139-2147.
46. Maheshri, N.; Koerber, J.T.; Kaspar, B.K.; Schaffer, D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol., 2006, 24(2), 198-204.
47. Perabo, L.; Goldnau, D.; White, K.; Endell, J.; Boucas, J.; Humme, S.; Work, L. M.; Janicki, H.; Hallek, M.; Baker, A.H.; Buning, H. Heparan sulfate proteoglycan binding properties of adenoassociated virus retargeting mutants and consequences for their in vivo tropism. J. Virol., 2006, 80(14), 7265-7269.
48. Maersch, S.; Huber, A.; Buning, H.; Hallek, M.; Perabo, L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology, 2010, 397(1), 167-175.
49. Grimm, D.; Lee, J.S.; Wang, L.; Desai, T.; Akache, B.; Storm, T. A.; Kay, M.A. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol., 2008, 82(12), 5887-5911.
50. Koerber, J.T.; Jang, J.H.; Schaffer, D.V. DNA shuffling of adenoassociated virus yields functionally diverse viral progeny. Mol. Ther., 2008, 16(10), 1703-1709.
51. Green, N.K.; Morrison, J.; Hale, S.; Briggs, S.S.; Stevenson, M.; Subr, V.; Ulbrich, K.; Chandler, L.; Mautner, V.; Seymour, L.W.; Fisher, K.D. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med., 2008, 10(3), 280-289. doi: 10.1002/jgm.1121.
52. Romberg, B.; Hennink, W.E.; Storm, G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res., 2008, 25(1), 55-71.
53. Hofherr, S.E.; Mok, H.; Gushiken, F.C.; Lopez, J.A.; Barry, M.A. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum. Gene Ther., 2007, 18(9), 837-848.
54. Oh, I.K.; Mok, H.; Park, T.G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug. Chem., 2006, 17(3), 721-727.
55. Croyle, M.A.; Cheng, X.; Wilson, J.M. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther., 2001, 8(17), 1281-1290.
56. Bartel, M.; Schaffer, D.; Buning, H. Enhancing the clinical potential of AAV vectors by capsid engineering to evade pre-existing immunity. Front Microbiol., 2011, 2, 204.
57. Lee, G.K.; Maheshri, N.; Kaspar, B.; Schaffer, D.V. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. 2005.
58. Lee, W.K.; Park, J.Y.; Jung, S.; Yang, C.W.; Kim, W.U.; Kim, H.Y.; Park, J.H.; Park, J.S. Preparation and characterization of biodegradable nanoparticles entrapping immunodominant peptide conjugated with PEG for oral tolerance induction. J. Control Release, 2005, 105(1-2), 77-88.
59. Mingozzi, F.; High, K.A. Immune responses to AAV in clinical trials. Curr. Gene Ther., 2011, 11(4), 321-330.
60. Stasi, R.; Brunetti, M.; Stipa, E.; Amadori, S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood, 2004, 103(12), 4424-4428.
61. Okada, T.; Takeda, S. Current challenges and future directions in recombinant AAV-mediated gene therapy of duchenne muscular dystrophy. Pharmaceuticals (Basel), 2013, 6(7), 813-836.
62. Mingozzi, F.; Chen, Y.; Murphy, S.L.; Edmonson, S.C.; Tai, A.; Price, S.D.; Metzger, M.E.; Zhou, S.; Wright, J.F.; Donahue, R.E.; Dunbar, C.E.; High, K.A. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol. Ther., 2012, 20(7), 1410-6.
63. Unzu, C.; Hervas-Stubbs, S.; Sampedro, A.; Mauleon, I.; Mancheno, U.; Alfaro, C.; de Salamanca, R.E.; Benito, A.; Beattie, S. G.; Petry, H.; Prieto, J.; Melero, I.; Fontanellas, A. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J. Transl. Med., 2012, 10, 122.
64. Nathwani, A.C.; Cochrane, M.; McIntosh, J.; Ng, C.Y.; Zhou, J.; Gray, J. T.; Davidoff, A. M., Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther., 2009, 16(1), 60-69.
65. Finn, J.D.; Hui, D.; Downey, H.D.; Dunn, D.; Pien, G.C.; Mingozzi, F.; Zhou, S.; High, K.A. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol. Ther., 2010, 18(1), 135-142.
66. Karman, J.; Gumlaw, N.K.; Zhang, J.; Jiang, J.L.; Cheng, S.H.; Zhu, Y.I. Proteasome inhibition is partially effective in attenuating pre-existing immunity against recombinant adeno-associated viral vectors. PLoS One, 2012, 7(4), e34684.
67. Halbert, C.L.; Standaert, T.A.; Wilson, C.B.; Miller, A.D. Successful read ministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol., 1998, 72(12), 9795-805.
68. Zhu, J.; Huang, X.; Yang, Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J. Clin. Invest., 2009, 119(8), 2388-2398.
69. Lorain, S.; Gross, D.A.; Goyenvalle, A.; Danos, O.; Davoust, J.; Garcia, L. Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Mol. Ther., 2008, 16(3), 541-7.
70. Nathwani, A.C.; Tuddenham, E.G.; Rangarajan, S.; Rosales, C.; McIntosh, J.; Linch, D.C.; Chowdary, P.; Riddell, A.; Pie, A.J.; Harrington, C.; O'Beirne, J.; Smith, K.; Pasi, J.; Glader, B.; Rustagi, P.; Ng, C.Y.; Kay, M.A.; Zhou, J.; Spence, Y.; Morton, C.L.; Allay, J.; Coleman, J.; Sleep, S.; Cunningham, J.M.; Srivastava, D.; Basner-Tschakarjan, E.; Mingozzi, F.; High, K.A.; Gray, J.T.; Reiss, U.M.; Nienhuis, A.W.; Davidoff, A.M. Adenovirusassociated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 2011, 365(25), 2357-2365.
71. Nayak, S.; Herzog, R.W. Progress and prospects: Immune responses to viral vectors. Gene Ther., 2010, 17(3), 295-304.
72. Nayak, S.; Cao, O.; Hoffman, B.E.; Cooper, M.; Zhou, S.; Atkinson, M.A.; Herzog, R.W. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J. Thromb. Haemost., 2009, 7(9), 1523-1532.
73. Monteilhet, V.; Saheb, S.; Boutin, S.; Leborgne, C.; Veron, P.; Montus, M. F.; Moullier, P.; Benveniste, O.; Masurier, C. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther., 2011, 19(11), 2084-2091.
74. Faust, S.M.; Bell, P.; Cutler, B.J.; Ashley, S.N.; Zhu, Y.; Rabinowitz, J.E.; Wilson, J.M., CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest., 2013, 123(7), 2994-3001.
75. Mays, L.E.; Wilson, J.M. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther., 2010, 19(1), 16-27.
76. Hareendran, S.; Balakrishnan, B.; Sen, D.; Kumar, S.; Srivastava, A.; Jayandharan, G.R., Adeno-associated virus (AAV) vectors in gene therapy: Immune challenges and strategies to circumvent them. Rev. Med. Virol., 2013, 23(6), 399-413. doi: 10.1002/rmv.1762.
77. Balakrishnan, B.; Sen, D.; Hareendran, S.; Roshini, V.; David, S.; Srivastava, A.; Jayandharan, G.R. Activation of the cellular unfolded protein response by recombinant adeno-associated virus vectors. PLoS One, 2013, 8(1), e53845.
78. Mingozzi, F.; Anguela, X. M.; Pavani, G.; Chen, Y.; Davidson, R. J.; Hui, D.J.; Yazicioglu, M.; Elkouby, L.; Hinderer, C.J.; Faella, A.; Howard, C.; Tai, A.; Podsakoff, G.M.; Zhou, S.; Basner-Tschakarjan, E.; Wright, J. F.; High, K. A. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci. Translational Med., 2013, 5(194), 194ra92.
79. Muller, O.J.; Kaul, F.; Weitzman, M.D.; Pasqualini, R.; Arap, W.; Kleinschmidt, J.A.; Trepel, M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol., 2003, 21(9), 1040-1046.
80. McCraw, D.M.; O'Donnell, J.K.; Taylor, K.A.; Stagg, S.M.; Chapman, M.S. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology, 2012, 431(1-2), 40-49.
81. Gurda, B.L.; Raupp, C.; Popa-Wagner, R.; Naumer, M.; Olson, N. H.; Ng, R.; McKenna, R.; Baker, T.S.; Kleinschmidt, J.A.; Agbandje-McKenna, M. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol., 2012, 86(15), 7739-7751.
82. Simonelli, F.; Maguire, A.M.; Testa, F.; Pierce, E.A.; Mingozzi, F.; Bennicelli, J.L.; Rossi, S.; Marshall, K.; Banfi, S.; Surace, E.M.; Sun, J.; Redmond, T.M.; Zhu, X.; Shindler, K.S.; Ying, G.S.; Ziviello, C.; Acerra, C.; Wright, J.F.; McDonnell, J.W.; High, K.A.; Bennett, J.; Auricchio, A. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol. Ther., 2010, 18(3), 643-650.
83. Calcedo, R.; Vandenberghe, L. H.; Gao, G.; Lin, J.; Wilson, J. M. Worldwide epidemiology of neutralizing antibodies to adenoassociated viruses. J. Infect. Dis., 2009, 199(3), 381-390.
84. Calcedo, R.; Morizono, H.; Wang, L.; McCarter, R.; He, J.; Jones, D.; Batshaw, M.L.; Wilson, J.M. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin. Vaccine Immunol., 2011, 18(9), 1586-1588.
85. Britten, C.M.; Walter, S.; Janetzki, S. Immunological monitoring to rationally guide AAV gene therapy. Front Immunol., 2013, 4, 273.
86. Herzog, R. W. Immune responses to AAV capsid: are mice not humans after all? Mol. Ther., 2007, 15(4), 649-650.
87. Herzog, R.W.; Davidoff, A.M.; Markusic, D.M.; Nathwani, A.C. AAV vector biology in primates: Finding the missing link? Mol. Ther., 2011, 19(11), 1923-1924.
88. Mingozzi, F.; Maus, M.V.; Hui, D.J.; Sabatino, D.E.; Murphy, S.L.; Rasko, J.E.; Ragni, M.V.; Manno, C.S.; Sommer, J.; Jiang, H.; Pierce, G.F.; Ertl, H.C.; High, K.A. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med., 2007, 13(4), 419-422.
89. Sun, J.Y.; Anand-Jawa, V.; Chatterjee, S.; Wong, K.K. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther., 2003, 10(11), 964-976.
90. Cao, O.; Hoffman, B.E.; Moghimi, B.; Nayak, S.; Cooper, M.; Zhou, S.; Ertl, H. C.; High, K.A.; Herzog, R.W. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol. Ther., 2009, 17(10), 1733-1742.
91. Wekerle, H.; Flugel, A.; Fugger, L.; Schett, G.; Serreze, D. Autoimmunity's next top models. Nat., Med., 2012, 18(1), 66-70.
92. Akkina, R. New generation humanized mice for virus research: Comparative aspects and future prospects. Virology, 2013, 435(1), 14-28.
93. Washburn, M.L.; Bility, M.T.; Zhang, L.; Kovalev, G.I.; Buntzman, A.; Frelinger, J.A.; Barry, W.; Ploss, A.; Rice, C.M.; Su, L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology, 2011, 140(4), 1334-1344.
94. Flotte, T.; Carter, B.; Conrad, C.; Guggino, W.; Reynolds, T.; Rosenstein, B.; Taylor, G.; Walden, S.; Wetzel, R., A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum. Gene Ther., 1996, 7(9), 1145-1159.
95. Bryant, L.M.; Christopher, D.M.; Giles, A.R.; Hinderer, C.; Rodriguez, J.L.; Smith, J.B.; Traxler, E.A.; Tycko, J.; Wojno, A.P.; Wilson, J.M. Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev., 2013, 24(2), 55-64.
96. Tseng, Y.S.; Agbandje-McKenna, M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front Immunol., 2014, 5, 9.
97. Rogers, G.L.; Martino, A.T.; Aslanidi, G.V.; Jayandharan, G.R.; Srivastava, A.; Herzog, R.W. Innate immune responses to AAV vectors. Front Microbiol., 2011, 2.
98. Cao, O.; Armstrong, E.; Schlachterman, A.; Wang, L.; Okita, D.K.; Conti-Fine, B.; High, K.A.; Herzog, R.W. Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX. Blood, 2006, 108(2), 480-486.
99. Herzog, R.W. Hepatic AAV gene transfer and the immune system: Friends or foes? Mol. Ther., 2010, 18(6), 1063-1066.
100. Dobrzynski, E.; Fitzgerald, J.C.; Cao, O.; Mingozzi, F.; Wang, L.; Herzog, R.W. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc. Natl. Acad. Sci. U.S.A, 2006, 103(12), 4592-4597.
101. Li, H.; Lasaro, M.O.; Jia, B.; Lin, S.W.; Haut, L.H.; High, K.A.; Ertl, H.C. Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates. Mol. Ther., 2011, 19(11), 2021-2030.
102. Hoffman, B.E.; Herzog, R.W. Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Mol. Ther., 2013, 21(9), 1648-1650.
103. Cao, O.; Dobrzynski, E.; Wang, L.; Nayak, S.; Mingle, B.; Terhorst, C.; Herzog, R.W. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood, 2007, 110(4), 1132-1140.
104. Mingozzi, F.; Liu, Y.L.; Dobrzynski, E.; Kaufhold, A.; Liu, J.H.; Wang, Y.; Arruda, V.R.; High, K.A.; Herzog, R.W. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin. Invest., 2003, 111(9), 1347-1356.
105. Fields, P.A.; Kowalczyk, D.W.; Arruda, V.R.; Armstrong, E.; McCleland, M.L.; Hagstrom, J.N.; Pasi, K.J.; Ertl, H.C.; Herzog, R. W.; High, K.A. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther., 2000, 1(3), 225-235.
106. Cottard, V.; Valvason, C.; Falgarone, G.; Lutomski, D.; Boissier, M. C.; Bessis, N. Immune response against gene therapy vectors: Influence of synovial fluid on adeno-associated virus mediated gene transfer to chondrocytes. J. Clin. Immunol., 2004, 24(2), 162-9.
107. Erles, K.; Sebokova, P.; Schlehofer, J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol., 1999, 59(3), 406-11.
108. Georg-Fries, B.; Biederlack, S.; Wolf, Jr.; Zur Hausen, H., 1984.
109. Hildinger, M.; Auricchio, A.; Gao, G.; Wang, L.; Chirmule, N.; Wilson, J. M. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J. Virol., 2001, 75(13), 6199-6203.
110. Xiao, W.; Chirmule, N.; Berta, S.C.; McCullough, B.; Gao, G.; Wilson, J. M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol., 1999, 73(5), 3994-4003.
111. Halbert, C. L.; Miller, A. D.; McNamara, S.; Emerson, J.; Gibson, R. L.; Ramsey, B.; Aitken, M. L. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther., 2006, 17(4), 440-447.
112. Boutin, S.; Monteilhet, V.; Veron, P.; Leborgne, C.; Benveniste, O.; Montus, M. F.; Masurier, C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther., 2010, 21(6), 704-712.
113. Sabatino, D. E.; Mingozzi, F.; Hui, D. J.; Chen, H.; Colosi, P.; Ertl, H. C.; High, K. A., Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol. Ther., 2005, 12(6), 1023-1033.
114. Chen, J.; Wu, Q.; Yang, P.; Hsu, H. C.; Mountz, J. D. Determination of specific CD4 and CD8 T cell epitopes after AAV2-and AAV8-hF.IX gene therapy. Mol. Ther., 2006, 13(2), 260-269.